Learn More >

Ministry Status: Routine Monitoring and Engagement

Patient Evidence Submissions

Drug Review Schedule

The Ontario Public Drug Program is currently accepting submissions of patient evidence on the following drug products which will undergo review by the Committee to Evaluate Drugs within the next 12 months.

Drug products on this list include new chemical entities, new combination products and existing drug products with a new indication recently approved by Health Canada. At this time, drug products that are line extensions (such as additional strengths and new dosage forms) and drug products that are undergoing reconsideration (second review, etc.) will not be considered for patient submissions. The Ministry will re-evaluate this once additional experience on the process is gained.

For drug products accepted for Rapid Review process, best efforts will be made to provide maximal time for patient submissions. However, in view of the intent of Rapid Review, the review of a drug product accepted for Rapid Review will not be held if only to include presentation of patient submissions.

Registered patient groups are invited to provide patient evidence on any of the drugs listed below.

All submissions must be received by 5:00pm of the deadline date.

Generic Name Brand Name Manufacturer Indication / Type of Review Deadline for Patient Submissions
Mepolizumab Nucala GlaxoSmithKline Inc. Asthma, severe eosinophilic (request to fund new autoinjector and pre-filled syringe dosage formats) November 27, 2019
Cabergoline Various Various Reimbursement criteria review to consider use as a first-line medication therapy for patients with hyperprolactinemia November 1, 2019
Quinagolide Norprolac Ferring Inc. Reimbursement criteria review to consider use as a first-line medication therapy for patients with hyperprolactinemia November 1, 2019
Daptomycin Cubicin RF Sunovion Pharmaceuticals Canada Inc Vancomycin-resistant enterococci bacteremia November 1, 2019
Leuprolide acetate Zeulide Depot Verity Pharmaceuticals Prostate cancer, advanced and/or metastatic November 1, 2019
Epinephrine Allerject Kaleo Inc. Anaphylactic reactions, emergency treatment November 25, 2019
Epinephrine Emerade Bausch Health Canada Inc. Anaphylactic reactions, emergency treatment November 25, 2019

See also:

Image:Pdf icon.gif To view PDF format files, you need to have Adobe Acrobat® Reader installed on your computer.
You can download this free software from the Adobe Web site.

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY (416)327-4282
Hours of operation: Monday to Friday, 8:30am - 5:00pm

 
  • Connect With Us
Facebook Twitter YouTube RSS